Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
October 1, 2025
-
BUSINESS Parexel Exec Says FDA Keeps Reviews on Track amid Staff Cuts, but Notes Leadership Drain
September 30, 2025
-
COMMENTARY FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
-
BUSINESS Industry Fears Trump’s MFN Drug Pricing Push Could Deepen Japan’s Lag and Loss
September 29, 2025
-
REGULATORY Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
-
REGULATORY Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
-
REGULATORY Pharma Support Needed to Bridge Biotech’s “Valley of Death”: Council Member
September 26, 2025
-
BUSINESS Nippon Zoki Shooting for 50% Overseas Sales by FY2035
September 25, 2025
-
BUSINESS Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
-
REGULATORY FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing
September 24, 2025
-
REGULATORY Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
-
ORGANIZATION JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
-
REGULATORY FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
-
REGULATORY J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
-
BUSINESS Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
-
BUSINESS Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
-
BUSINESS LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
-
BUSINESS Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
-
BUSINESS Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…